Abstract:Abstract Background Cancer stem cells (CSCs) are considered as the major cause to tumor initiation, recurrence, metastasis, and drug resistance, driving poor clinical outcomes in patients. Long noncoding RNAs (lncRNAs) have emerged as crucial regulators in cancer development and progression. However, limited lncRNAs involved in CSCs have been reported. Methods The novel lncROPM (a regulator of phospholipid metabolism) in breast CSCs (BCSCs) was identified by microarray and validated by qRT-PCR in BCSCs from breast cancer cells and tissues. The clinical significance of lncROPM was evaluated in two breast cancer cohorts and TANRIC database (TCGA-BRCA, RNAseq data). Gain- and loss-of-function assays were performed to examine the role of lncROPM on BCSCs both in vitro and in vivo. The regulatory mechanism of lncROPM was investigated by bioinformatics, RNA FISH, RNA pull-down, luciferase reporter assay, and actinomycin D treatment. PLA2G16-mediated phospholipid metabolism was determined by UHPLC-QTOFMS system. Cells’ chemosensitivity was assessed by CCK8 assay. Results LncROPM is highly expressed in BCSCs. The enhanced lncROPM exists in clinic breast tumors and other solid tumors and positively correlates with malignant grade/stage and poor prognosis in breast cancer patients. Gain- and loss-of-function studies show that lncROPM is required for the maintenance of BCSCs properties both in vitro and in vivo. Mechanistically, lncROPM regulates PLA2G16 expression by directly binding to 3'-UTR of PLA2G16 to increase the mRNA stability. The increased PLA2G16 significantly promotes phospholipid metabolism and the production of free fatty acid, especially arachidonic acid in BCSCs, thereby activating PI3K/AKT, Wnt/β-catenin, and Hippo/YAP signaling, thus eventually involving in the maintenance of BCSCs stemness. Importantly, lncROPM and PLA2G16 notably contribute to BCSCs chemo-resistance. Administration of BCSCs using clinic therapeutic drugs such as doxorubicin, cisplatin, or tamoxifen combined with Giripladib (an inhibitor of cytoplasmic phospholipase A2) can efficiently eliminate BCSCs and tumorigenesis. Conclusions Our study highlights that lncROPM and its target PLA2G16 play crucial roles in sustaining BCSC properties and may serve as a biomarker for BCSCs or other cancer stem cells. Targeting lncROPM-PLA2G16 signaling axis may be a novel therapeutic strategy for patients with breast cancer.

Targeting LRP8 inhibits breast cancer stem cells in triple-negative breast cancer

RON Receptor Tyrosine Kinase in Tumorigenic Stemness As a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.

LRP11-AS1 promotes the proliferation and migration of triple negative breast cancer cells via the miR-149-3p/NRP2 axis

The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways.

The Wnt/β-catenin signaling pathway: a potential therapeutic target in the treatment of triple negative breast cancer

EGFR inhibition blocks cancer stem cell clustering and lung metastasis of triple negative breast cancer

A novel lncRNA ROPM-mediated lipid metabolism governs breast cancer stem cell properties

Inhibitory Effect of the Novel Tyrosine Kinase Inhibitor DCC-2036 on Triple-Negative Breast Cancer Stem Cells Through AXL-KLF5 Positive Feedback Loop

Kruppel-like factor 8 regulates triple negative breast cancer stem cell-like activity

KK-LC-1 as a therapeutic target to eliminate ALDH+ stem cells in triple negative breast cancer

TRIM8 Inhibits Breast Cancer Proliferation by Regulating Estrogen Signaling

Targeting Brain-Adaptive Cancer Stem Cells Prohibits Brain Metastatic Colonization of Triple-Negative Breast Cancer

Targeting LRP6: A new strategy for cancer therapy

Novel Ways of Targeting Triple Negative Breast Cancer (TNBC) with the Latest Research - will it Improve Prognoses

Targeting RAS guanyl releasing protein 1 promotes T lymphocytes infiltrations and improves anti‐programmed death receptor ligand 1 therapy response of triple‐negative breast cancer

BCL9/BCL9L Promotes Tumorigenicity Through Immune-Dependent and Independent Mechanisms in Triple Negative Breast Cancer

TRIM8 Inhibits Breast Cancer Proliferation by Regulating Estrogen Signaling.

LHRH‐Targeted Redox‐Responsive Crosslinked Micelles Impart Selective Drug Delivery and Effective Chemotherapy in Triple‐Negative Breast Cancer

Targeting cancer-associated adipocyte-derived CXCL8 inhibits triple-negative breast cancer progression and enhances the efficacy of anti-PD-1 immunotherapy

Targeting Cancer Stem Cell Plasticity in Triple-Negative Breast Cancer.

Targeted inhibition of Wnt signaling with a bacterial toxin fragment suppresses breast cancer tumor-initiating/chemo-resistant cells